Seino Yoshie, Hirose Hiroshi, Saito Ikuo, Itoh Hiroshi
Department of Internal Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Metabolism. 2009 Mar;58(3):355-60. doi: 10.1016/j.metabol.2008.10.008.
Adiponectin is an adipocyte-specific secretory protein, which possesses antidiabetic and antiatherosclerotic properties. Adiponectin exists as multimers in serum, and high-molecular-weight (HMW) adiponectin is particularly considered to be the active form of the protein. The objective of the present study was to examine whether decreased HMW adiponectin is a predictor of progression to metabolic syndrome during a 6-year follow-up period in Japanese men. The study subjects were 416 Japanese men without metabolic syndrome, aged 30 to 59 years at baseline, who had participated in annual health checkups in both 2000 and 2006. Low concentration of HMW adiponectin (< or =2.65 microg/mL) was associated with substantially higher hazard ratio of the progression to metabolic syndrome after adjustment for age and body mass index (hazard ratio, 1.561; 95% confidence interval, 1.051-2.292; P = .028). The number of subjects with the progression to metabolic syndrome in each tertile based on baseline HMW adiponectin concentration was significantly different among the 3 groups (HMW adiponectin: chi(2) = 7.473, P = .0238; total adiponectin: chi(2) = 4.477, P = .1066; HMW-total adiponectin ratio: chi(2) = 1.676, P = .4325). It was suggested that decreased HMW adiponectin is a predictor of the progression to metabolic syndrome in a 6-year follow-up study of Japanese men. Furthermore, it was suggested longitudinally that measuring HMW adiponectin is efficient to predict the progression to metabolic syndrome compared with measuring total adiponectin or HMW-total adiponectin ratio.
脂联素是一种脂肪细胞特异性分泌蛋白,具有抗糖尿病和抗动脉粥样硬化特性。脂联素在血清中以多聚体形式存在,其中高分子量(HMW)脂联素被特别认为是该蛋白的活性形式。本研究的目的是检验在对日本男性进行的6年随访期内,HMW脂联素水平降低是否是代谢综合征进展的预测指标。研究对象为416名无代谢综合征的日本男性,基线年龄为30至59岁,他们在2000年和2006年都参加了年度健康检查。在调整年龄和体重指数后,低浓度的HMW脂联素(≤2.65微克/毫升)与代谢综合征进展的风险比显著更高相关(风险比,1.561;95%置信区间,1.051 - 2.292;P = 0.028)。基于基线HMW脂联素浓度的三分位数分组中,三组间代谢综合征进展的受试者数量有显著差异(HMW脂联素:χ² = 7.473,P = 0.0238;总脂联素:χ² = 4.477,P = 0.1066;HMW - 总脂联素比值:χ² = 1.676,P = 0.4325)。在对日本男性进行的6年随访研究中,提示HMW脂联素水平降低是代谢综合征进展的预测指标。此外,纵向研究表明,与测量总脂联素或HMW - 总脂联素比值相比,测量HMW脂联素对预测代谢综合征进展更有效。